

EXHIBIT C



215 Wood Ave., Middletown, NJ 08846
(732) 868-1090 Fax: (732) 868-1091
Web: <http://www.corepharma.com>

April 25, 2006

Frommer Lawrence & Haug LLP
745 Fifth Avenue
New York, NY 10151

Attn: Edgar Haug

Re: Notice of Patent Certification – U.S. Patent Nos. 5,326,570 and 5,912,013; ANDA No. 78-159 for Carbamazepine Extended Release Capsules

Dear Ed:

This letter is in response to your letter dated April 14, 2006, requesting additional information related to the above-described matter. I have attached a signed copy of your letter in which you agree to keep all materials produced by Corepharma as Confidential. In addition, I have included samples of each of the Corepharma Products, and a CD which contains the following sections from Corpharma's ANDA No. 78-159:

1. Section 4: Comparison between Generic Drug and Reference Listed Drug
2. Section 5: Labeling
3. Section 6: Bioavailability/Bioequivalence
4. Section 7: Components and Composition
5. Section 8: Raw Materials: Active and Inactive Ingredients
6. Section 11: Manufacturing and Processing Instructions
7. Section 12: In-Process Controls
8. Section 14: Controls for the Finished Dosage Form
9. Section 15: Analytical Methods for Drug Substance and Drug Product.
10. Table 5: Formulation Data from Section 6 of Corepharma's ANDA.



REDACTED



REDACTED



REDACTED

REDACTED

I am confident that the above information is more than enough to allow you to conduct a thorough analysis of the Corepharma Products, and to dissuade you from pursuing baseless litigation. Please be advised that the Federal Circuit clearly stated in *Loctite v. Ultraseal*, 781 F. 2nd 861 (1985) that it is an antitrust violation to assert a patent known not to be infringed.

Very truly yours,

A handwritten signature in black ink, appearing to read 'Gregory P. Young'.

Gregory P. Young
CEO